| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 35.5 | 44.6 | 35.5 |
| Other income | 1.5 | 4.3 | 2.1 |
| Total income | 37.0 | 49.0 | 37.6 |
| Profit before exceptional items & tax | 6.8 | 17.7 | 10.2 |
| Exceptional items | 0.0 | 4.0 | 0.0 |
| Profit before tax | 6.8 | 13.7 | 10.2 |
| Net profit | 5.9 | 10.8 | 7.8 |
| Operating margin | 18.4% | 28.0% | 27.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -24.40% |
|---|---|
| Net profit, quarter on quarter | -45.40% |
| Revenue, year on year | +0.00% |
| Operating profit, year on year | -34.60% |
| Operating profit, quarter on quarter | -60.40% |
BSE results filing, NSE: JENBURPH. Figures extracted from the filing.
Jenburkt Pharmaceuticals Ltd: key numbers
- Share price
- ₹948.40
- Market cap
- ₹418.6 Cr
- Revenue (annual)
- ₹168.7 Cr
- Net profit (annual)
- ₹34.74 Cr
- P/E (TTM)
- 12.8×Sector 50.4×
- Promoter holding
- 46.62%-0.02% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jenburkt Pharmaceuticals Ltd
All →Jenburkt Pharmaceuticals Other Announcement
Jenburkt Pharmaceuticals clarified its shares are permitted to trade on NSE without a listing application. The shares remain listed on BSE under the Permitted to Trade category.
Jenburkt Pharmaceuticals Management Change
Mr. Vinay Bhatt, Senior Vice President- International Business, has resigned from Jenburkt Pharmaceuticals Limited effective September 18, 2026, due to personal reasons.
Jenburkt Pharmaceuticals Annual General Meeting
Jenburkt Pharmaceuticals held its 41st Annual General Meeting on 4th September, 2026, to discuss financial statements, dividend declaration, and director appointments.
Jenburkt Pharmaceuticals Management Change
Jenburkt Pharmaceuticals elevated Shri Prem Ashish Bhuta to Associate Vice President – Strategic Initiatives. He is now classified as Senior Management Personnel effective September 4, 2026.
Jenburkt Pharmaceuticals Q4 FY26 Results: Net Profit ₹34.7 Cr, Up 8.1% YoY
Jenburkt Pharmaceuticals Ltd reported revenue from operations of ₹168.7 Cr (+11.2% YoY) and net profit of ₹34.7 Cr (+8.1% YoY) for Q4 FY26.
- Key figure
- Net profit ₹34.7 Cr · +8.1% YoY
Jenburkt Pharmaceuticals Q4 FY26 Results: Net Profit ₹10.8 Cr, Up 27.1% YoY
Jenburkt Pharmaceuticals Ltd reported revenue from operations of ₹44.6 Cr (+8.8% YoY) and net profit of ₹10.8 Cr (+27.1% YoY) for Q4 FY26.
- Key figure
- Net profit ₹10.8 Cr · +27.1% YoY